Our short, quick and targeted approach mixes qualitative and quantitative analysis. By applying market data, history, science and quantitative methods; we synthesize metrics of pricing the RegMed universe. RMI incorporates market dynamics, answering crucial questions and generating actionable investment recommendations.
Understanding and knowing the answer as the release is issued requires a historical knowledge of sector pricing to more than “questimate” share perception and rebounds.
January 26, 2017
RegMed Investors’ (RMi) mid-day analysis, pricing is jockeying
January 24, 2017
RegMed Investors’ (RMi) mid-day analysis, slam, bam and no thank you
January 19, 2017
Stemline Therapeutics (STML) proposes 4.5 M share $45 M offering, priced at $10.00
January 18, 2017
Pluristem (PSTI) upsizes share offering to 12.22 M shares with 50% warrant coverage priced at $1.225
January 12, 2017
Histogenics (HSGX) Jumps 40.79% in pre-market
January 11, 2017
RegMed Investors’ (RMi) mid-day analysis, stocks stumble in minutes
January 11, 2017
Sangamo Therapeutics (SGMO) orphan drug designation to SB-318
January 9, 2017
Aduro Biotech (ADRO) Clinical Collaboration with Merck (MRK) - BUY
January 5, 2017
Cesca Therapeutics receives (KOOL) FDA approval for significant revisions to its pivotal study?
January 5, 2017
Fate Therapeutics (FATE) First Patient Treated in ProTmune™ PROTECT Clinical Trial
January 5, 2017
Sangamo BioSciences (SGMO) FDA Clears IND Application
January 5, 2017
Fibrocell Science (FCSC) FDA Fast Track Designation of FCX-007
January 4, 2017
Spark Therapeutics (ONCE) $15 M milestone payment from Pfizer (PFE)
January 3, 2017
Kite Pharma (KITE) submits an IND to initiate a P1 trial of KITE-718 and jumps +2.34%
December 20, 2016
Northwest Bio (NWBO) another 28.6 M share RDO priced at $0.35 and 50% warrant coverage for proceeds of $10 M
December 20, 2016
BioLife Solutions (BLFS) new supply client, TissueGene
December 20, 2016
Pluristem Therapeutics (PSTI) term sheet for new corporation in Japan to commercialize PLX-PAD for Critical Limb Ischemia (CLI)
December 15, 2016
Vericel (VCEL) proposes 6.2 M share $17 M offering at $2.75
December 14, 2016
Brainstorm Cell Therapeutics (BCLI) new data from its P2 study of NurOwn – SELL into strength
December 14, 2016
Kite Pharma (KITE) strategic partnership with Vitruvian Networks - BUY
December 14, 2016
Organovo ONVO) exclusive distributor agreement with Cosmo Bio (JASDAQ:3386) for its NovoView Preclinical Services in Japan - BUY
December 12, 2016
World Stem Cell Summit, a past week of cell therapy and regenerative medicine
December 12, 2016
Kite Pharma (KITE) characterizes of T cell receptor candidates
November 29, 2016
Vericel (VCEL) investor converts Series A Preferred Stock
My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.
My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.
Do you have an opinion you would like to share with us? We would like to hear from you.
Please e-mail us at hwm@regmedinvestors.com.
Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors
© 2026 RegMed Investors (regmedinvestors.com), all rights are reserved.
RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.
The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.
The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.